Q2041 Axicabtagene ciloleucel car+
Also known as: Yescarta, axicabtagene ciloleucel, CAR-T
Axicabtagene ciloleucel CAR+ therapy, chimeric antigen receptor T-cell immunotherapy for CD19-positive B-cell malignancies.
In Plain Language
cancer cell fighter; engineered cell therapy
Clinical Context
Used for relapsed/refractory large B-cell lymphomas and multiple myeloma. Engineered T-cells target CD19+ cancer cells. Requires hospitalization for infusion and monitoring.
RVU Information
CPT Q2041 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q2041?
CPT Q2041 (Axicabtagene ciloleucel car+) is a Q Codes code. Axicabtagene ciloleucel CAR+ therapy, chimeric antigen receptor T-cell immunotherapy for CD19-positive B-cell malignancies.
Is Q2041 covered by insurance?
Q2041 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for relapsed/refractory large B-cell lymphomas and multiple myeloma. Engineered T-cells target CD19+ cancer cells. Requires hospitalization for infusion and monitoring.
When is CPT Q2041 used?
Used for relapsed/refractory large B-cell lymphomas and multiple myeloma. Engineered T-cells target CD19+ cancer cells. Requires hospitalization for infusion and monitoring.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.